WORLD FIRST: China approves Neuracle NEO as world's first commercially cleared invasive BCI — March 13, 2026
Summary
China's National Medical Products Administration (NMPA) granted marketing approval on March 13, 2026 to Neuracle Medical Technology for NEO — the world's first commercially approved invasive brain-computer interface product. Jointly developed with Tsinghua University, NEO is a coin-sized wireless implant placed on the brain's outer surface that decodes motor intent in real time to control a pneumatic robotic glove for grasping. It is approved for adults aged 18-60 with tetraplegia from cervical SCI who retain some upper arm function. Chinese BCI company shares surged on the news, with Shenzhen-listed Inkon Life Technology rising over 10%.
Why it matters
The world's first commercial approval for an invasive BCI is a defining moment in neurotechnology history — the equivalent of the first commercial pacemaker approval in 1960 for cardiac devices. China beating the US to first commercial BCI clearance reshapes the geopolitical narrative of the BCI race entirely. Every BCI company, investor, and regulator worldwide must now reassess timelines in light of what NMPA has just demonstrated is possible.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial